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INTRODUCTION
Breast conserving surgery has been shown by numerous prospec-
tive studies to have the same survival rate as total mastectomy, and 
has currently taken a position alongside modified radical mastec-
tomy as the standard surgical procedure for breast cancer [1-4]. 
With the increased rate of the early diagnosis of breast cancer 
through health checkups, breast conserving surgery has steadily 
become more common. However, while the chance of local recur-
rence gradually disappears with total mastectomy, patients who 
undergo breast conserving surgery are known to be in constant 
danger of local recurrence, even over the course of long-term fol-
low-up [1]. It is not yet known whether such local recurrence is a 
manifestation of systemic metastasis or is simply due to the aggres-
sive behavior of the tumor. However, some research supports the 
proposal that local recurrence is associated with an increased like-
lihood of systemic metastasis, and according to research conduct-
ed by the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG), reducing four local recurrences during the first five 
years can reduce one deathe due to breast cancer after 15 years [5-
8]. Hence, understanding the risk factors of local recurrence and 
reducing the likelihood of local recurrence is of the utmost impor-
tance.
Positive margins are a major risk factor for local recurrence after 
breast conserving surgery. Typically, total mastectomy is conduct-
ed when negative margins cannot be achieved after numerous re-
sections [9,10]. In addition, young age has also been reported to be 
a major risk factor for local recurrence after breast-conserving sur-
gery (BCS) [8,11,12]. Hence, many questions have been raised re-
garding the safety of breast conserving surgery in young breast 
cancer patients, and the National Comprehensive Cancer Network 
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guidelines state that young patients should not undergo BCS. 
However, some recent prospective research has reported that the 
survival rate did not differ between young patients who received 
total mastectomy and those who underwent BCS, suggesting that 
breast conserving surgery should not be avoided due to age alone 
[13,14].
Meanwhile, the standards for classifying patients as young have 
varied across studies, with some considering patients under 50 to 
be young, and others considering those under 35 to be young. A 
recent study on the appropriate age range to be considered young, 
conducted among patients registered in the Korean Breast Cancer 
Registration Program, concluded that 35 and below is the appro-
priate boundary [15]. This study observed the prognoses of Kore-
an patients age 35 or below who underwent either a total mastec-
tomy or breast conserving surgery to verify the oncological safety 
of breast conserving surgery in young Asian patients.
METHODS
Patients and subjects
From January 1981 to April 2008, a total of 5,366 patients under-
went surgery due to invasive breast cancer at the surgery depart-
ment of the College of Medicine of Yonsei University. Of these pa-
tients, 547 patients were aged 35 and below. The research was con-
ducted only on patients with pathologically confirmed stage 1 or 2 
breast cancer, and excluded patients who received chemotherapy 
prior to surgery or had cancer in both breasts. Of the remaining 
371 patients, 1 was excluded due to the absence of records regard-
ing the surgical method, and another 3 were excluded because they 
had not received radiation treatment. This resulted in a final total 
of 367 patients, 245 of whom had undergone a total mastectomy, 
while the remaining 122 had undergone breast conserving surgery. 
Factors such as the age at the time of diagnosis, histologic subtype, 
size of the tumor, axillary lymph node metastasis, staging, histolog-
ic grade, hormone receptor status, surgical method, margin status, 
whether radiation treatment was performed, whether chemother-
apy was administered after surgery, and whether endocrine thera-
py was administered were recorded.
Simple local recurrence was defined as a recurrence in the chest 
wall, including the skin, in the area of the operation for total mas-
tectomy, and was defined as recurrence in the skin and/or breast 
on the side of the operation for BCS. Recurrence in only the re-
gional lymph nodes was excluded. The time until simple local re-
currence was calculated as the time between the day of operation 
to the day of recurrence. Simple local recurrence was limited to re-
currence in the breast that was operated upon. Hence, cases where 
regional or systemic recurrence occurred either first or simultane-
ously were excluded. In such cases, observation was ceased on the 
day that recurrence was discovered in a different area. Local or 
whole-body recurrence within 6 months of recurrence in the op-
erated breast was treated as simultaneous recurrence. Systemic re-
currence was defined as recurrence in an area beyond the operated 
breast and the regional lymph nodes. The systemic recurrence free 
survival period extended from the day of the operation to the day 
on which systemic recurrence was verified, and observations were 
ceased on the date of death or on the date of the final hospital visit. 
The total survival period was defined as extending from the date of 
surgery to the date of death, regardless of the cause. The final prog-
ress observation date was fixed at March 31, 2011. This research 
was conducted under the approval of the Severance Hospital Insti-
tutional Review Board (Approval no. 4-2016-1162).
Statistical methods
The 2 patient groups were compared with the independent t-test 
for continuous variables, and the chi-square test for categorical 
variables. The survival curve was obtained using the Kaplan-Meier 
method, and the 2 patient groups were compared using the log-
rank test. A Cox proportional hazards model was used to verify 
that the surgical method was an independent prognostic factor. All 
statistical analyses were conducted using SPSS ver. 13.0 (SPSS Inc., 
Chicago, IL, USA), and P-values from the 2-sided test less than or 
equal to 0.05 were considered to indicate statistical significance.
RESULTS
Clinical characteristics
Table 1 shows the characteristics of the patients and the tumors, 
along with the treatment method. The median age for both patient 
groups was 32.0 years. The T staging was higher in the patients 
who underwent a total mastectomy (P = 0.005) and, while not sta-
tistically significant, this group also showed higher N staging 
(P = 0.086). Hence, based on the tumor characteristics, it would be 
predicted that the patients who underwent a total mastectomy 
would have a worse prognosis. However, there were no differences 
in the systemic treatment received by both groups. Of the 122 pa-
tients who underwent BCS, negative margins were obtained in 
115, while 2 patients had positive margins. There were no records 
for the remaining 5 patients.
Local recurrence
In 13 patients, isolated local recurrence took place after BCS; of 
these patients, recurrence was diagnosed in 3 within 2 years of sur-
gery, in another 2 from 2 to 5 years after surgery, in 3 from 5 to 10 
years after surgery, and in 4 after 10 years. The patients continued 
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to be diagnosed with isolated local recurrence throughout the ob-
servation period. In contrast, only 4 patients who received total 
mastectomy were diagnosed with isolated local recurrence, and in 
all 4, recurrence was diagnosed within 3 years. The 2 patients who 
had positive margins in breast conserving surgery did not experi-
ence local recurrence during the observation period.
The isolated local recurrence rate in the patients who received 
BCS was 7.7% within 5 years and 20.3% within 10 years, both of 
which were higher than the corresponding rates in the patients 
who underwent total mastectomy (P < 0.001), who had an isolated 
local recurrence of 1.9% for both 5 and 10 years (Fig. 1). It was 
found that chemotherapy reduced the isolated local recurrence 
rate (P = 0.019) in patients who underwent breast conserving sur-
gery; this trend was found for all patients, albeit with a weaker ef-
fect (P = 0.05) (Table 2, Fig. 2).
The isolated local recurrence rate in the patients who underwent 
breast conserving surgery and received chemotherapy was 5% 
within 5 years and 10.6% within 10 years. Factors such as the age at 
the time of diagnosis, T and N staging, the presence of estrogen re-
ceptors, and whether endocrine therapy was applied did not affect 
the isolated local recurrence rate. However, the surgical method did 
affect the isolated local recurrence rate (P < 0.028), even after cor-
recting for age at the time of diagnosis and T staging (Tables 2, 3). 
Overall survival rate
The 5-year overall survival rate for the patients who underwent 
breast conserving surgery was 85.7%, while the 10-year overall sur-
vival rate was 87.1%. Meanwhile, the patients who underwent total 
mastectomy had a 5-year overall survival rate of 87.1% and a 10-
year overall survival rate of 78.2%. The overall survival rate did not 
significantly differ between the 2 groups (P = 0.689) (Fig. 1). Ac-
Table 1. Characteristics of patients aged 35 years or younger un-
dergoing breast conserving surgery (BCS) or mastectomy  
Characteristic
BCS 
(n=122)
Mastectomy 
(n=245)
P-value
Age (yr)
   ≤ 30
   > 30
 
43 (35.2)
79 (64.8)
 
72 (30.1)
167 (69.9)
0.323
Tumor size (pT)
   T1
   T2
 
67 (54.9)
55 (45.1)
 
97 (39.6)
148 (60.4)
0.005
Nodal status (pN)
   0
   1–3
 
90 (73.8)
32 (26.2)
 
159 (64.9)
86 (35.1)
0.086
Grade
   1, 2
   3
   Unknown
 
56 (62.9)
33 (37.1)
33
 
95 (68.8)
43(31.2)
107
0.356
Estrogen receptor
   Negative
   Positive
   Unknown
 
57 (54.8)
47 (45.2)
18
 
66 (41.0)
95 (59.0)
84
0.028
Chemotherapy
   Done
   Not done
   Unknown
 
94 (77.0)
28 (23.0)
0
 
193 (80.8)
46 (19.2)
6
0.41
Endocrine therapy
   Done
   Not done
   Unknown
 
40 (32.8)
82 (67.2)
0
 
87 (37.7)
144 (62.3)
14
0.364
Adjuvant systemic therapy
   Done
   Not done
   Unknown
 
99 (81.1)
23(18.9)
0
 
204 (85.4)
35 (14.6)
6
0.303
Radiotherapy
   Yes
   No
   Unknown
 
122 (100.0)
0 (0.0)
0
 
16 (7.0)
213 (93.0)
16
< 0.001
Values are presented as number (%).   
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Fig. 1. (A) Isolated local recurrence-free survival and (B) overall survival curves according to local treatment in patients aged ≤35 years. BCS, 
breast-conserving surgery.
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cording to the univariate analysis, N staging was the only prognos-
tic factor that affected the overall survival rate (P < 0.0001), while 
those under the age of 30 at the time of diagnosis tended to have a 
lower overall survival rate (P = 0.082). In the multivariate analysis 
that included age at the time of diagnosis, T staging, N staging, sur-
gical method, and chemotherapy as covariates, N staging (P 
< 0.001) and age at the time of diagnosis (P = 0.037) appeared to be 
prognostic factors that affected the overall survival rate (Tables 4, 5). 
Of the patients who experienced isolated local recurrence, 3 died 
during the observation period; both these patients were diagnosed 
Table 2. Univariate analysis of isolated LR for breast cancer patients aged 35 years or less    
Characteristic No. 5-yr LR rate (standard error) 10-yr LR rate (standard error) P-value
Age
   ≤ 30 yr
   > 30 yr
 
115
246
 
3.0 (1.7)
3.9 (1.5)
 
5.5 (3.0)
8.1 (3.5)
0.63
pT stage
   I
   II
 
164
203
 
4.9 (2.1)
2.5 (1.2)
 
10.4 (4.5)
4.0 (1.9)
0.176
pN stage
   I
   II
 
249
118
 
3.7 (1.4)
3.2 (1.9)
 
8.4 (3.1)
3.2 (1.9)
0.549
Grade
   1, 2
   3
 
151
76
 
5.7 (2.1)
0
 
8.0 (3.1)
7.7 (7.4)
0.21
Estrogen receptor
   Negative
   Positive
 
123
142
 
4.7 (2.6)
5.4 (2.2)
 
8.6 (4.5)
7.8 (3.2)
0.585
Operation method
   Mastectomy
   BCS
 
245
122
 
1.9 (0.9)
7.7 (3.2)
 
1.9 (0.9)
20.3 (7.7)
< 0.001
Adjuvant chemotherapy
   Not done
   Done
 
74
287
 
5.1 (3.0)
3.1 (1.2)
 
12.2 (5.6)
4.3 (1.7)
0.05
Adjuvant endocrine therapy
   Not done
   Done
 
226
127
 
3.4 (1.4)
4.1 (2.0)
 
8.0 (3.0)
4.1 (2.0)
0.975
LR, local recurrence; pT, pathologic T stage; pN, pathologic N stage; BCS, breast conservaing surgery.    
Table 3. Multivariate analysis of isolated local recurrence for breast 
cancer patients aged 35 years or less 
Characteristic
Relative risk 
(confidence interval)
P-value
Age (≤ 30 yr vs. > 30 yr) 0.996 (0.342–2.897) 0.993
T stage (I vs. II) 1.295 (0.445–3.769) 0.636
Operation method (mastectomy vs. BCS) 0.114 (0.035–0.366) < 0.001
Adjuvant chemotherapy (not done vs. done) 2.090 (0.732–5.969) 0.168
BCS, breast conservaing surgery.  
Table 4. Multivariate analysis of isolated local recurrence for breast 
cancer patients aged 35 years or less who had breast conserving 
treatment
Characteristic
Relative risk 
(confidence interval)
P-value
Age (≤ 30 yr vs. > 30 yr) 1.847 (0.503–6.787) 0.356
T stage (I vs. II) 0.812 (0.198–3.319) 0.771
Adjuvant chemotherapy 
 (not done vs. done)
4.802 (1.186–19.439) 0.028
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Fig. 2. Isolated local recurrence-free survival curve according to the 
administration of chemotherapy in patients aged ≤35 years.
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with isolated local recurrence within 2 years of surgery.
DISCUSSION
Surgery for breast cancer is gradually developing from radical sur-
gery to advanced surgical procedures that allow for oncological 
safety and improve quality of life. Hence, BCS for breast cancer 
surgery has become more common, and sentinel lymph node bi-
opsy is also slowly becoming the standard for axillary lymph node 
surgery. Although there have been conflicting reports regarding 
whether patients who undergo a total mastectomy have a higher 
quality of life than those who undergo BCS, studies conducting 
long-term observations have established that patients who under-
go BCS tend to have a higher quality of life [16-18]. However, on-
cological safety is as important as quality of life. Many prospective 
randomized studies have verified the oncological safety of BCS. 
However, these studies have included a limited number of breast 
cancer patients under the age of 35, making it difficult to ensure 
the oncological safety of BCS in patients under the age of 35. 
Hence, this study attempted to verify the oncological safety of BCS 
in patients under the age of 35.
To summarize the results of this study, although the isolated lo-
cal recurrence rate was higher in the patients who underwent BCS 
than in those who underwent a total mastectomy, there were no 
differences in the overall survival rate, and chemotherapy lowered 
the isolated local recurrence rate in the patients who underwent 
BCS. This research only observed isolated local recurrences that 
were not systemic. The reason for this is that if both systemic me-
tastasis and local recurrence occur simultaneously, the systemic 
metastasis typically determines the prognosis; hence, the prognosis 
of the local recurrence under such circumstances lacks clinical 
meaning.
There was a clear difference in the isolated local recurrence rate 
between the patients who underwent BCS and those who under-
went a total mastectomy. Of the 5 patients who received BCS, 1 pa-
tient experienced recurrence in the breast that was operated upon 
within 10 years of surgery (under the age of 45) and required addi-
tional treatment. If isolated local recurrence influences the survival 
rate, BCS in patients under the age of 35 could be considered dan-
gerous. However, although the patients who underwent BCS had a 
higher isolated local recurrence rate in this study, the overall sur-
vival rate did not differ between the 2 groups. It is possible that the 
number of patients and the observation period were both insuffi-
cient to verify differences in the total survival rate. However, a 
study that compared the 10-year survival rate in a much larger pa-
tient sample likewise reported no differences in the overall survival 
rate, despite differences in the local recurrence rate [13,14].
Although some studies have reported that systemic metastasis 
increased as the isolated local recurrence rate increased, those 
studies failed to verify the causality between isolated local recur-
rence and systemic metastasis [6,8]. However, according to the re-
sults of the EBCTCG study, reducing local recurrence can reduce 
death from breast cancer in the long term. Hence, until the clinical 
significance of the prognosis of isolated local recurrence is clari-
fied, this result cannot be ignored. Although there is no need to 
ban BCS in patients under the age of 35 simply due to the higher 
rate of isolated local recurrence, there is a need for sufficient con-
sultation with the patient prior to surgery and, if the decision is 
made to proceed with BCS, adjuvant treatment should be provid-
ed to reduce the chance of local recurrence.
According to the findings of the present study, adjuvant chemo-
therapy was effective in reducing the isolated local recurrence rate. 
This effect has also been verified in other studies [19]. Further-
more, the general belief that local recurrence within a short period 
after BCS is associated with a bad prognosis was confirmed in this 
research, as all patients diagnosed with isolated local recurrence 
who died during the observation period were diagnosed within 2 
years of surgery [8]. Hence, patients who are diagnosed with isolat-
ed local recurrence within 2–3 years of surgery must actively par-
ticipate not only in local treatment, but in systemic treatment as 
well.
However, this study is limited in that it is a retrospective analysis 
that only analyzed patients who received long-term treatment at a 
single facility. Furthermore, there were differences in the tracking 
period between the patients who received BCS and the patients 
who received total mastectomy, and detailed analyses including the 
medication used for chemotherapy were not conducted, despite 
developments in breast cancer treatment that could have distorted 
the results due to changes in the adjuvant treatments. Furthermore, 
this study did not analyze certain other factors that could have af-
fected the overall survival rate, such as characteristics of the recur-
rent tumors and local and systemic treatment after recurrence. 
Hence, follow-up research that overcomes the limitations of this 
Table 5. Multivariate analysis of overall survival for breast cancer 
patients aged 35 years or less  
Characteristic
Relative risk 
(confidence interval)
P-value
Age (≤ 30 yr vs. > 30 yr) 1.800 (1.035–3.130) 0.037
T stage (I vs. II) 0.700 (0.387–1.266) 0.238
N stage (I vs. II) 0.318 (0.177–0.573) < 0.001
Operation method (mastectomy vs. BCS) 1.040 (0.552–1.961) 0.902
Adjuvant chemotherapy (not done vs. done) 1.532 (0.737–3.183) 0.253
BCS, breast conservaing surgery.  
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study is required.
For breast cancer patients under the age of 35, the likelihood of 
isolated local recurrence after BCS is much higher than that after 
total mastectomy. Although there is no need to prohibit BCS just 
because the patient is under the age of 35, chemotherapy based on 
the age at the time of diagnosis and the risk level of recurrence 
should be considered to reduce the possibility of isolated local re-
currence. In order to produce accurate guidelines on the oncologi-
cal safety of BCS in breast cancer patients under the age of 35, fur-
ther research exploring the clinical significance of isolated local re-
currence for the prognosis is required.
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